Objective: To investigate the efficacy and safety of plerixafor combined with granulocyte colony-stimulating factor (G-CSF) in mobilizing peripheral blood hematopoietic stem cells in patients with lymphoma.
Methods: The clinical data of lymphoma patients who received autologous hematopoietic stem cell mobilization using plerixafor combined with G-CSF from January 2019 to December 2021 were retrospectively analyzed. The patients received 3 kinds of mobilization regimens: front-line steady-state mobilization, preemptive intervention, and recuse mobilization. The acquisition success rate, excellent rate of collection, and incidence of treatment-related adverse reaction were counted. The influence of sex, age, disease remission status, bone marrow involvement at diagnosis, chemotherapy lines, number of chemotherapy, platelet count and number of CD34+ cells on the day before acquisition in peripheral blood on the collection results were analyzed to identify the risk factors associated with poor stem cell collection.
Results: A total of 43 patients with lymphoma were enrolled, including 7 cases who received front-line steady-state mobilization, 19 cases who received preemptive intervention, and 17 cases who received recuse mobilization. The overall acquisition success rate was 58.1% (25/43) after use of plerixafor combined with G-CSF, and acquisition success rate of front-line steady-state mobilization, preemptive intervention, and recuse mobilization was 100%, 57.9%(11/19), and 41.2%(7/17), respectively. The excellent rate of collection was 18.6%(8/43). A total of 15 patients experienced mild to moderate treatment-related adverse reactions. The number of CD34+ cells < 5 cells/μl in peripheral blood on the day before collection was an independent risk factor affecting stem cell collection.
Conclusions: Plerixafor combined with G-CSF is a safe and effective mobilization regimen for patients with lymphoma. The number of CD34+ cells in peripheral blood on the day before collection is an predictable index for the evaluation of stem cell collection.
题目: 普乐沙福联合G-CSF动员淋巴瘤患者自体外周血造血干细胞的疗效及安全性分析.
目的: 分析普乐沙福联合粒细胞集落刺激因子（G-CSF）动员淋巴瘤患者自体外周血造血干细胞的有效性及安全性。.
方法: 回顾性分析2019年1月到2021年12月接受普乐沙福联合G-CSF进行自体造血干细胞动员的淋巴瘤患者的临床资料。普乐沙福的用药策略分为一线稳态动员、抢先干预及挽救性动员，对三种策略的采集成功率、优良率及治疗相关不良反应率进行统计，并对性别、年龄、疾病缓解状态、初诊时是否有骨髓累及、化疗线数、化疗次数、采集前一天血小板数及采集前一天外周血CD34+细胞数等因素对采集结果的影响进行分析。.
结果: 共纳入43例患者，其中7例为一线稳态动员，19例为抢先干预，17例为挽救性动员。使用普乐沙福联合G-CSF后，总体采集成功率为58.1%（25/43），一线稳态动员采集成功率为100%，抢先干预为57.9%（11/19），挽救性动员为41.2%（7/17）。采集优良率为18.6%（8/43）。共有15例患者出现轻中度治疗相关不良反应。采集前一天外周血CD34+细胞数<5个/μl是影响干细胞采集的独立危险因素。.
结论: 普乐沙福联合G-CSF是淋巴瘤患者安全有效的动员方案。采集前一天外周血CD34+细胞数是预测干细胞采集的有效指标。.
Keywords: CD34; hematopoietic stem cell mobilization; lymphoma; peripheral blood hematopoietic stem cell; plerixafor;.